There’s now a good deal of observational data suggesting that GLP-1s do indeed cut the chance of developing obesity-related cancer – possibly by up to 40 per cent. But we all know that correlation and causation are not the same thing. So a group of Manchester University academics is planning to run a large study aimed at producing a definitive answer. They […]
First-in-class oral therapy ATR-258 mimics the effects of exercise – driving fat loss, increasing muscle, and improving metabolism – with broad potential as a novel treatment for muscle-sparing weight loss Study led by Associate Professor Morten Hostrup, a leading authority on β2-adrenergic receptor signaling in skeletal muscle at the University of Copenhagen, to evaluate muscle […]
Back in mid-January Optimum’s Hot Topics column took a look at life expectancy data and asked the rather depressing question: “Will you live longer than your parents – or not?” Why so downbeat? Because besides stalling life expectancy figures, a slew of other data also seemed to hint that longevity might have peaked: steadily growing […]
OZEMPIC, Wegovy, Mounjaro, Zepbound: they’ve quickly become part of our vocabulary. In just a few years, powerful GLP-1 drugs, first introduced to control Type 2 diabetes but now much better known for their ability to help people rapidly lose weight, have become indispensable weapons in the Battle of the Bulge. In the UK alone, some […]
